Acidex, Compound Alginate Oral Suspension, Heartburn and Indigestion Liquid - PL 04917/0021

Summary of Product Characteristics Updated 07-Mar-2019 | Pinewood Healthcare

1. Name of the medicinal product

Acidex Aniseed Flavour Oral Suspension

Asda Heartburn and Indigestion Liquid

Boots Heartburn Relief Aniseed Flavour

Galpharm Heartburn and Indigestion Relief Oral Suspension

LloydsPharmacy Heartburn and Indigestion Liquid

Peptac Liquid, Heartburn and Indigestion Liquid

Heartburn and Indigestion relief

Sainsbury's Healthcare Heartburn and Indigestion Oral Suspension

Superdrug Heartburn and Indigestion Oral Suspension

Wilkinson Heartburn and Indigestion Liquid

Essential Waitrose Heartburn and Indigestion Oral Suspension

Morrisons Heartburn and Indigestion Oral Suspension

Numark Heartburn and Indigestion Oral Suspension

Healthpoint Heartburn and Indigestion Oral Suspension

2. Qualitative and quantitative composition

Each 5 ml contains:

Sodium Bicarbonate BP

133.5 mg

Sodium Alginate BP

250 mg

Calcium Carbonate BP

80 mg

Also contains parahydroxybenzoates. For a full list of excipients, see section 6.1

3. Pharmaceutical form

Aniseed Flavoured Pink Suspension

4. Clinical particulars
4.1 Therapeutic indications

This medicine alleviates the painful conditions resulting from the reflux of gastric acid and bile into the oesophagus by suppressing the reflux itself. It is indicated in heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia, reflux oesophagitis, regurgitation and all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.

4.2 Posology and method of administration

For oral use

Adults and children over 12 years:

Two to four 5 ml spoonfuls.

Children 6 - 12 years:

One to two 5 ml spoonfuls

Not recommended in children under six years of age.

Doses should be taken after meals and at bedtime.

4.3 Contraindications

This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients listed in section 6.1, including ethyl parahydroxybenzoate (E214) and propyl parahydroxybenzoate (E216) (see section 4.4).

4.4 Special warnings and precautions for use

Each 10 ml dose of this medicine contains about 6 mmoles of sodium and therefore care should be exercised in patients on a sodium restricted diet.

Each 10 ml dose contains 160 mg (1.6 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

This medicine should not be taken within 1 to 2 hours of taking other medicines by mouth

If symptoms do not improve after seven days, the clinical situation should be reviewed.

This medicine should not be used by patients allergic to any of its constituents.

Parahydroxybenzoates (E214 and E216): may cause allergic reactions (possibly delayed).

4.5 Interaction with other medicinal products and other forms of interaction

A time-interval of 2 hours should be considered between this medicine intake and the administration of other medicinal products, especially tetracyclines, digoxine, fluoroquinolone, iron salt, ketoconazole, neuroleptics, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propanolol), glucocorticoid, chloroquine and biphosphonates (diphosphonates) and estramustine. See also 4.4.

Antacids may interact with other drugs as they alter the gastric pH which may affect dissolution, solubility or ionization of the other drug. Antacids reduce the absorption of certain drugs from the following groups: ACE Inhibitors, Analgesics, Antibacterials, Antiepileptics, Antifungals, Antimalarials, Antipsychotics, Bisphosphonates, Penicillamine.

Antacids may increase the pH of the urine and affect the rate of drug elimination. Excretion of basic drugs is decreased whereas acidic drugs are eliminated more rapidly.

Due to effects at the renal level sodium bicarbonate may reduce plasma lithium levels and increase plasma quinidine levels.

4.6 Fertility, pregnancy and lactation

Pregnancy:

Clinical studies in more than 500 pregnant women as well as a large amount of data from postmarketing experience indicate no malformative nor feto / neonatal toxicity of the active substances. This medicine can be used during pregnancy, if clinically needed.

Breast feeding:

No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. This medicine can be used during breast-feeding.

Fertility:

Pre-clinical investigations have revealed alginate has no negative effect on parental or offspring fertility or reproduction.

Clinical data do not suggest that this medicine has an effect on human fertility.

4.7 Effects on ability to drive and use machines

There are no effects on ability to drive or operate machinery.

4.8 Undesirable effects

Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

System Organ Class

Frequency

Adverse Event

Immune System Disorders

Very rare

Anaphylactic and anaphylactoid reactions.

Hypersensitivity reactions such as urticaria.

Respiratory, Thoracic and Mediastinal Disorders

Very rare

Respiratory effects such as bronchospasm.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website :www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store

4.9 Overdose

As this medicine mode of action is physical, overdosage in terms of the alginate content is virtually no hazard. The only consequence is abdominal distension which is best treated conservatively. The relatively low concentrations of sodium and calcium carbonate in this medicine would also make serious consequences from overdosage very unlikely.

5. Pharmacological properties
5.1 Pharmacodynamic properties

On ingestion the product reacts rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents, quickly and effectively impeding gastrooesophageal reflux, for up to 4 hours. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect.

5.2 Pharmacokinetic properties

Alginic acid is not absorbed into the systemic circulation.

5.3 Preclinical safety data

There is no Preclinical Safety Data.

6. Pharmaceutical particulars
6.1 List of excipients

Carbomer (Carbopol 974P)

Sodium Hydroxide

Saccharin Sodium

Ethyl parahydroxybenzoate (E214)

Propyl parahydroxybenzoate (E216)

Butyl parahydroxybenzoate

Isopropyl Alcohol

Erythrosine Colour (E127)

Star Anise Oil

Purified Water

6.2 Incompatibilities

None known.

6.3 Shelf life

24 months - amber glass bottles

18 months - HDPE bottles

15 months – PET bottles

6.4 Special precautions for storage

Do not store above 25°C. Do not refrigerate.

6.5 Nature and contents of container

Pharmaceutical Grade III amber glass bottles with pilfer proof caps and tamper evident screw caps.

High density polyethylene bottles with tamper evident screw caps.

PET bottle with tamper evident screw caps.

Pack sizes: 50ml, 100ml, 150ml, 200ml, 250ml, 300ml and 500ml.

50ml (PET)

6.6 Special precautions for disposal and other handling

Not applicable.

7. Marketing authorisation holder

Pinewood Laboratories Limited,

Ballymacarbry,

Clonmel,

Co. Tipperary.

8. Marketing authorisation number(s)

PL 4917/0021

9. Date of first authorisation/renewal of the authorisation

25/03/1998

10. Date of revision of the text

08/01/2019

Company Contact Details
Pinewood Healthcare
Address

Ballymacarby, Clonmel, Co. Tipperary, Co. Tipperary, Ireland

Telephone

+353 52 6186000

Medical Information Direct Line

+44 1978 661 261

Medical Information Fax

+44 1978 661 702

WWW

http://www.pinewood.ie

Fax

+ 353 52 6136311

Medical Information e-mail